As the flu season begins, the FDA has issued significant approvals of new products for diagnosing and treating the disease. New Flu Assays On October 24, Abbott announced that the FDA has granted CLIA waivers for its next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing. The new assays…
FDA Watch: Agency Approves New Flu Tests and Drug
by Glenn S. Demby | Dec 14, 2018 | FDA-nir, National Lab Reporter